Dr Marina Garassino speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the analysis of NSCLC patients with brain and liver metastases in the KEYNOTE 189 trial.

Dr Garassino states the frequency of brain and liver metastases in this disease type, along with the association with decreased prognosis in NSCLC patients.

She also describes the details of KEYNOTE 189 study, where investigators examined the effect of pembrolizumab plus pemetrexed and platinum-based chemotherapy as treatment for metastatic NSCLC.

Prof Garassino discusses the endpoints examined during the trial; in which the treatment regimen displayed an overall survival benefit and increased progression-free survival, just one year into the trial.

She also mentions that this treatment regimen has already been approved in several countries, with more countries expected to follow.